Roper Technologies

Roper Technologies

Yahoo Finance • 3 days ago

Roche Holding (SWX:ROP) Ebola Testing Support Keeps Fair Value In Focus

Roche Holding (SWX:ROP) has been back in focus after Roche Diagnostics shipped two molecular testing instruments to support Ebola response efforts in the Democratic Republic of Congo, tying humanitarian work directly to the diagnostics seg... Full story

Yahoo Finance • 3 days ago

Roche (SWX:ROP) Stock Looks Undervalued Despite Recent Pipeline Progress

Roche Holding has delivered a strong multi year share price run, and with the stock last closing at CHF 360.00 the live question is whether that price still lines up with what its earnings support. Recent product milestones and licensing d... Full story

Yahoo Finance • 4 days ago

Is Roper Technologies (ROP) Trading At A Discount To Cash Flow?

Roper Technologies has had a rough stretch on the market, which raises a straightforward question for you as an investor: Is the current share price still in line with what the company's cash flows can justify? The stock is down 30.4% ove... Full story

Yahoo Finance • 4 days ago

Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC

Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC. Roche will preconfigure the instruments and train local laboratory technicians bef... Full story

Yahoo Finance • 5 days ago

Stock futures rise after Nasdaq hits record high

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Stock index futures were higher on Tuesday, a day after the Nasdaq Composite touched a record high while investors looked ahead to trade data and comments from Federal Res... Full story

Yahoo Finance • 8 days ago

3 European Defensive Stocks Investors Are Watching As Bond Markets Turn Risk Off

Bond markets are throwing out fresh stress signals, with investors racing toward German Bunds and dumping riskier debt across Europe. That kind of flight to safety can punish cyclical stocks and fragile balance sheets, yet it can also shin... Full story

Yahoo Finance • 11 days ago

Roche launches newborn screening test for three severe genetic conditions

This test expands Roche's early diagnostics portfolio by screening for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) simultaneously. Catching these conditions shortly after bi... Full story

Yahoo Finance • 14 days ago

Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships

Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody can... Full story

Yahoo Finance • 18 days ago

Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues

Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in onco... Full story

Yahoo Finance • 18 days ago

Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?

Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared w... Full story

Yahoo Finance • 23 days ago

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

F. Hoffmann-La Roche Ltd Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated... Full story

Yahoo Finance • 24 days ago

Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma

Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio'... Full story

Yahoo Finance • 24 days ago

ROP Benefits From Strength in Application Software Unit: Can the Momentum Sustain?

Roper Technologies, Inc. ROP is gaining from continued momentum in the Application Software segment. In the second quarter of 2026, ROP's Application Software segment accounted for nearly 56% of Roper's total revenues. The segment revenues... Full story

Yahoo Finance • 24 days ago

Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study

F. Hoffmann-La Roche Ltd Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular... Full story

Yahoo Finance • 26 days ago

Illumia Appoints Don Smith to Lead Higher Education Portfolio

New role brings Illumia's higher education commerce, identity and payments businesses under one leader SCOTTSDALE, Ariz., September 15, 2026--(BUSINESS WIRE)--Illumia, a leading provider of technology solutions that power payments, identi... Full story

Yahoo Finance • 27 days ago

Procare Solutions Acquires Playground, Combining Industry Leading Expertise with Innovative, AI-Powered Child Care Technology

DENVER, Sept. 14, 2026 /PRNewswire/ -- Procare Solutions, a leader in AI-enabled child care management software, trusted by more than 40,000 centers nationwide, announced today it has acquired Playground, a modern, all-in-one child care ma... Full story

Yahoo Finance • 29 days ago

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

F. Hoffmann-La Roche Ltd Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achie... Full story

Yahoo Finance • last month

U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments

F. Hoffmann-La Roche Ltd If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) Filing acceptance is based on the Phase III METEOROID study s... Full story

Yahoo Finance • last month

Roper Technologies to present at Piper Sandler Conference

Roper Technologies, Inc. SARASOTA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Piper Sandler Growth Frontiers Conference on Tuesday, September 15, 2026, at 8:30 AM... Full story

Yahoo Finance • last month

Stock index futures slide as Middle East tensions keep investors on edge

[Wall Street street sign in Manhattan financial district] Alexey_Fedoren Stock index futures were lower on Tuesday as Middle East tensions remained in focus, with Wall Street set to return after the Labor Day holiday. Dow futures (INDU [... Full story